AvalehtGLTO • NASDAQ
add
Galecto Inc
23,01 $
Pärast sulgemist:(6,13%)+1,41
24,42 $
Suletud: 31. dets, 18:34:04 GMT −5 · USD · NASDAQ · Välistus
Viimane sulgemishind
22,31 $
Tänane vahemik
22,33 $ - 24,75 $
Aasta vahemik
2,01 $ - 38,33 $
Turuväärtus
36,64 mln USD
Keskmine maht
148,14 tuh
P/E suhe
-
Dividendimäär
-
Põhibörs
NASDAQ
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (USD) | sept 2025info | Y/Y muutus |
|---|---|---|
Käive | — | — |
Põhitegevusega seonduv kulu | 3,16 mln | −17,81% |
Puhastulu | −3,13 mln | 19,31% |
Puhaskasumimarginaal | — | — |
Puhaskasum aktsia kohta | — | — |
EBITDA | −3,15 mln | 17,81% |
Tõhus maksumäär | — | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (USD) | sept 2025info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 7,61 mln | −61,35% |
Kogu vara | 10,74 mln | −54,07% |
Kõik kohustused | 2,73 mln | 11,80% |
Kogu omakapital | 8,01 mln | — |
Emiteeritud aktsiate arv | 1,33 mln | — |
Hinna ja väärtuse suhe P/B | 4,44 | — |
Varade tasuvus | −64,60% | — |
Kapitali tasuvus | −82,59% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (USD) | sept 2025info | Y/Y muutus |
|---|---|---|
Puhastulu | −3,13 mln | 19,31% |
Põhitegevuse rahakäive | −2,62 mln | 28,35% |
Investeeringute raha | — | — |
Finantseerimise raha | — | — |
Raha ja raha ekvivalentide muutus | −2,60 mln | 18,18% |
Tasuta rahavoog | −1,17 mln | 43,71% |
Teave
Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark.
The company builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Galecto's lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, in which there is high unmet medical need. Wikipedia
Tegevjuht
Asutatud
2011
Veebisait
Töötajate arv
5
